Detection of phenolic glycolipid-I antigen and antibody in sera from new and relapsed lepromatous patients treated with various drug regimens

Sangnae Cho, R. V. Cellona, T. T. Fajardo, R. M. Abalos, E. C. Dela Cruz, G. P. Walsh, J. D. Kim, P. J. Brennan

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Since phenolic glycolipid-I (PGL-I) is an unequivocal marker of Mycobacterium leprae, the antigen has been a good candidate for the serodiagnosis and monitoring the effectiveness of leprosy chemotherapy. As an effort to define the kinetics of the PGL-I antigen and its antibodies in leprosy patients, this study was initiated to examine the serum specimens obtained serially from lepromatous patients under chemotherapy trials. PGL-I was detectable in 64 (94.1%) of 68 new lepromatous (bacterial index, BI = 3.2 to 5.8) and in 26 (78.8%) of 33 relapsed lepromatous patients (BI = 3.0 to 5.3). Meanwhile, virtually all of the new and relapsed patients were strongly seropositive to PGL-I. PGL-I was not detectable in any of the patients about 18 months after chemotherapy was initiated; however, anti-PGL-I reactivity declined by 50% at 2 years and by about 70% at 5 years after chemotherapy regardless of the drug regimens under study. Considering the rapid disappearance of the PGL-I antigen and steady decrease in anti-PGL-I IgM antibodies following chemotherapy, the PGL-I-based serology may be useful for monitoring the effectiveness of treatment, at both the early and late stages, in leprosy patients whose initial sera contain a significant level of PGL-I antigen or antibodies.

Original languageEnglish
Pages (from-to)25-31
Number of pages7
JournalInternational Journal of Leprosy
Volume59
Issue number1
Publication statusPublished - 1991 Jan 1

Fingerprint

Glycolipids
Antibodies
Serum
Pharmaceutical Preparations
Drug Therapy
Leprosy
I-antigen
Mycobacterium leprae
Serologic Tests
Serology
Immunoglobulin M
Antigens

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Cho, S., Cellona, R. V., Fajardo, T. T., Abalos, R. M., Dela Cruz, E. C., Walsh, G. P., ... Brennan, P. J. (1991). Detection of phenolic glycolipid-I antigen and antibody in sera from new and relapsed lepromatous patients treated with various drug regimens. International Journal of Leprosy, 59(1), 25-31.
Cho, Sangnae ; Cellona, R. V. ; Fajardo, T. T. ; Abalos, R. M. ; Dela Cruz, E. C. ; Walsh, G. P. ; Kim, J. D. ; Brennan, P. J. / Detection of phenolic glycolipid-I antigen and antibody in sera from new and relapsed lepromatous patients treated with various drug regimens. In: International Journal of Leprosy. 1991 ; Vol. 59, No. 1. pp. 25-31.
@article{1dab6f95d2ed4385bcca51eec3118d4e,
title = "Detection of phenolic glycolipid-I antigen and antibody in sera from new and relapsed lepromatous patients treated with various drug regimens",
abstract = "Since phenolic glycolipid-I (PGL-I) is an unequivocal marker of Mycobacterium leprae, the antigen has been a good candidate for the serodiagnosis and monitoring the effectiveness of leprosy chemotherapy. As an effort to define the kinetics of the PGL-I antigen and its antibodies in leprosy patients, this study was initiated to examine the serum specimens obtained serially from lepromatous patients under chemotherapy trials. PGL-I was detectable in 64 (94.1{\%}) of 68 new lepromatous (bacterial index, BI = 3.2 to 5.8) and in 26 (78.8{\%}) of 33 relapsed lepromatous patients (BI = 3.0 to 5.3). Meanwhile, virtually all of the new and relapsed patients were strongly seropositive to PGL-I. PGL-I was not detectable in any of the patients about 18 months after chemotherapy was initiated; however, anti-PGL-I reactivity declined by 50{\%} at 2 years and by about 70{\%} at 5 years after chemotherapy regardless of the drug regimens under study. Considering the rapid disappearance of the PGL-I antigen and steady decrease in anti-PGL-I IgM antibodies following chemotherapy, the PGL-I-based serology may be useful for monitoring the effectiveness of treatment, at both the early and late stages, in leprosy patients whose initial sera contain a significant level of PGL-I antigen or antibodies.",
author = "Sangnae Cho and Cellona, {R. V.} and Fajardo, {T. T.} and Abalos, {R. M.} and {Dela Cruz}, {E. C.} and Walsh, {G. P.} and Kim, {J. D.} and Brennan, {P. J.}",
year = "1991",
month = "1",
day = "1",
language = "English",
volume = "59",
pages = "25--31",
journal = "International Journal of Leprosy and Other Mycobacterial Diseases",
issn = "0148-916X",
publisher = "Allen Press Inc.",
number = "1",

}

Cho, S, Cellona, RV, Fajardo, TT, Abalos, RM, Dela Cruz, EC, Walsh, GP, Kim, JD & Brennan, PJ 1991, 'Detection of phenolic glycolipid-I antigen and antibody in sera from new and relapsed lepromatous patients treated with various drug regimens', International Journal of Leprosy, vol. 59, no. 1, pp. 25-31.

Detection of phenolic glycolipid-I antigen and antibody in sera from new and relapsed lepromatous patients treated with various drug regimens. / Cho, Sangnae; Cellona, R. V.; Fajardo, T. T.; Abalos, R. M.; Dela Cruz, E. C.; Walsh, G. P.; Kim, J. D.; Brennan, P. J.

In: International Journal of Leprosy, Vol. 59, No. 1, 01.01.1991, p. 25-31.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Detection of phenolic glycolipid-I antigen and antibody in sera from new and relapsed lepromatous patients treated with various drug regimens

AU - Cho, Sangnae

AU - Cellona, R. V.

AU - Fajardo, T. T.

AU - Abalos, R. M.

AU - Dela Cruz, E. C.

AU - Walsh, G. P.

AU - Kim, J. D.

AU - Brennan, P. J.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Since phenolic glycolipid-I (PGL-I) is an unequivocal marker of Mycobacterium leprae, the antigen has been a good candidate for the serodiagnosis and monitoring the effectiveness of leprosy chemotherapy. As an effort to define the kinetics of the PGL-I antigen and its antibodies in leprosy patients, this study was initiated to examine the serum specimens obtained serially from lepromatous patients under chemotherapy trials. PGL-I was detectable in 64 (94.1%) of 68 new lepromatous (bacterial index, BI = 3.2 to 5.8) and in 26 (78.8%) of 33 relapsed lepromatous patients (BI = 3.0 to 5.3). Meanwhile, virtually all of the new and relapsed patients were strongly seropositive to PGL-I. PGL-I was not detectable in any of the patients about 18 months after chemotherapy was initiated; however, anti-PGL-I reactivity declined by 50% at 2 years and by about 70% at 5 years after chemotherapy regardless of the drug regimens under study. Considering the rapid disappearance of the PGL-I antigen and steady decrease in anti-PGL-I IgM antibodies following chemotherapy, the PGL-I-based serology may be useful for monitoring the effectiveness of treatment, at both the early and late stages, in leprosy patients whose initial sera contain a significant level of PGL-I antigen or antibodies.

AB - Since phenolic glycolipid-I (PGL-I) is an unequivocal marker of Mycobacterium leprae, the antigen has been a good candidate for the serodiagnosis and monitoring the effectiveness of leprosy chemotherapy. As an effort to define the kinetics of the PGL-I antigen and its antibodies in leprosy patients, this study was initiated to examine the serum specimens obtained serially from lepromatous patients under chemotherapy trials. PGL-I was detectable in 64 (94.1%) of 68 new lepromatous (bacterial index, BI = 3.2 to 5.8) and in 26 (78.8%) of 33 relapsed lepromatous patients (BI = 3.0 to 5.3). Meanwhile, virtually all of the new and relapsed patients were strongly seropositive to PGL-I. PGL-I was not detectable in any of the patients about 18 months after chemotherapy was initiated; however, anti-PGL-I reactivity declined by 50% at 2 years and by about 70% at 5 years after chemotherapy regardless of the drug regimens under study. Considering the rapid disappearance of the PGL-I antigen and steady decrease in anti-PGL-I IgM antibodies following chemotherapy, the PGL-I-based serology may be useful for monitoring the effectiveness of treatment, at both the early and late stages, in leprosy patients whose initial sera contain a significant level of PGL-I antigen or antibodies.

UR - http://www.scopus.com/inward/record.url?scp=0025755228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025755228&partnerID=8YFLogxK

M3 - Article

C2 - 2030314

AN - SCOPUS:0025755228

VL - 59

SP - 25

EP - 31

JO - International Journal of Leprosy and Other Mycobacterial Diseases

JF - International Journal of Leprosy and Other Mycobacterial Diseases

SN - 0148-916X

IS - 1

ER -